ENLIVEN THERAPEUTICS, INC. Weighted Average Number of Shares Outstanding, Basic and Diluted
ENLIVEN THERAPEUTICS, INC. (ELVN) reported Weighted Average Number of Shares Outstanding, Basic and Diluted of 26.29 million shares for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-06.
Discontinued › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted · last filed 2022-05-06
- ENLIVEN THERAPEUTICS, INC. weighted average number of shares outstanding, basic and diluted for the quarter ending 2022-03-31 was 26.29M shares, a 49.55% increase year-over-year.
- ENLIVEN THERAPEUTICS, INC. weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-12-31 was 26.35M shares, a 49.61% increase year-over-year.
- ENLIVEN THERAPEUTICS, INC. weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-09-30 was 24.90M shares, a 43.51% increase year-over-year.
- ENLIVEN THERAPEUTICS, INC. weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-06-30 was 17.72M shares, a 3.03% increase year-over-year.
- ENLIVEN THERAPEUTICS, INC. weighted average number of shares outstanding, basic and diluted for fiscal 2021 was 21.66M shares, a 55.56% increase from fiscal 2020.
- ENLIVEN THERAPEUTICS, INC. weighted average number of shares outstanding, basic and diluted for fiscal 2020 was 13.92M shares, a 1882.29% increase from fiscal 2019.
- ENLIVEN THERAPEUTICS, INC. weighted average number of shares outstanding, basic and diluted for fiscal 2019 was 702.46K shares.
| Period end | Weighted Average Number of Shares Outstanding, Basic and Diluted 3 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 6 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 9 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 12 month |
|---|---|---|---|---|
| 2022-03-31 | 26.29M shares 10-Q · filed 2022-05-06 | 26.32M shares derived: average of 2 quarters · filed 2022-05-06 | 25.84M shares derived: average of 3 quarters · filed 2022-05-06 | 23.81M shares derived: average of 4 quarters · filed 2022-05-06 |
| 2021-12-31 | 26.35M shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | 25.62M shares derived: average of 2 quarters · filed 2022-03-15 | 22.99M shares derived: average of 3 quarters · filed 2022-03-15 | 21.66M shares 10-K · filed 2022-03-15 |
| 2021-09-30 | 24.90M shares 10-Q · filed 2021-11-09 | 21.31M shares derived: average of 2 quarters · filed 2021-11-09 | 20.10M shares 10-Q · filed 2021-11-09 | 19.45M shares derived: average of 4 quarters · filed 2022-05-06 |
| 2021-06-30 | 17.72M shares 10-Q · filed 2021-08-06 | 17.65M shares 10-Q · filed 2021-08-06 | 17.63M shares derived: average of 3 quarters · filed 2022-05-06 | 17.56M shares derived: average of 4 quarters · filed 2022-05-06 |
| 2021-03-31 | 17.58M shares 10-Q · filed 2022-05-06 | 17.59M shares derived: average of 2 quarters · filed 2022-05-06 | 17.51M shares derived: average of 3 quarters · filed 2022-05-06 | 17.43M shares derived: average of 4 quarters · filed 2022-05-06 |
| 2020-12-31 | 17.61M shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | 17.48M shares derived: average of 2 quarters · filed 2022-03-15 | 17.38M shares derived: average of 3 quarters · filed 2022-03-15 | 13.92M shares 10-K · filed 2022-03-15 |
| 2020-09-30 | 17.35M shares 10-Q · filed 2021-11-09 | 17.27M shares derived: average of 2 quarters · filed 2021-11-09 | 12.70M shares 10-Q · filed 2021-11-09 | 9.69M shares derived: average of 4 quarters · filed 2021-11-09 |
| 2020-06-30 | 17.19M shares 10-Q · filed 2021-08-06 | 10.34M shares 10-Q · filed 2021-08-06 | 7.13M shares derived: average of 3 quarters · filed 2021-08-06 | 5.52M shares derived: average of 4 quarters · filed 2021-08-06 |
| 2020-03-31 | 3.49M shares 10-Q · filed 2021-05-11 | 2.10M shares derived: average of 2 quarters · filed 2021-05-11 | 1.63M shares derived: average of 3 quarters · filed 2021-05-11 | 1.40M shares derived: average of 4 quarters · filed 2021-05-11 |
| 2019-12-31 | 702.29K shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-05 | 702.40K shares derived: average of 2 quarters · filed 2021-03-05 | 702.44K shares derived: average of 3 quarters · filed 2021-03-05 | 702.46K shares 10-K · filed 2021-03-05 |
| 2019-09-30 | 702.51K shares 10-Q · filed 2020-11-05 | 702.51K shares derived: average of 2 quarters · filed 2020-11-05 | 702.51K shares 10-Q · filed 2020-11-05 | |
| 2019-06-30 | 702.51K shares 10-Q · filed 2020-08-14 | 702.51K shares 10-Q · filed 2020-08-14 | ||
| 2019-03-31 | 702.51K shares 10-Q · filed 2020-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |